ZURICH, April 4 (Reuters) – Roche (ROG.S) said on Monday the U.S. Food and Drug administration granted priority review to its Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults.

Roche says U.S. FDA grants priority review to Actemra for COVID-19

A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012. REUTERS/Michael Buholzer/File Photo

“If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patients,” Roche said in a statement, adding that more than 1 million people hospitalised with COVID-19 had been treated with Actemra/RoActemra worldwide since the beginning of the pandemic.

Reporting by Silke Koltrowitz, Editing by Miranda Murray

Our Standards: The Thomson Reuters Trust Principles.


Reuters source: